Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 8/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | AMPD2 | Q01433 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL677674 | 0.80 | NOTUM (0.60) | NOTUMCYP2D6CYP2C9CES1HSD17B3 | |
| SCHEMBL9545365 | 0.72 | NOTUM (0.51) | NOTUMCYP2D6CYP2C9CES1HSD17B3 | |
| SCHEMBL1048074 | 0.72 | NOTUM (1.00) | NOTUMCYP2D6CYP2C9CES1HSD17B3 | |
| SCHEMBL30003296 | 0.72 | NOTUM (1.00) | NOTUMCYP2D6CYP2C9CES1HSD17B3 | |
| SCHEMBL14726015 | 0.71 | CYP2D6 (0.59) | NOTUMCYP2D6CYP2C9HSD17B3POLB | |
| SCHEMBL2335850 | 0.68 | AMPD2 (0.44) | CYP2D6CYP2C9HSD17B3POLBAMPD2 | |
| SCHEMBL68594 | 0.68 | NOTUM (0.72) | NOTUMCYP2D6CYP2C9HSD17B3KDM4E | |
| Bicarbonate SCHEMBL22393229 | 0.68 | ALOX15 (0.40) | CYP2D6CYP2C9NPC1RAB9APOLB | |
| SCHEMBL642025 | 0.67 | NOTUM (0.70) | NOTUMCYP2D6CYP2C9HSD17B3MAPT | |
| SCHEMBL8293539 | 0.67 | CYP2D6 (1.00) | NOTUMCYP2D6CYP2C9HSD17B3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS INC. (US) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | NOTUM 2781/4885CYP2D6 4629/4885CYP2C9 4830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.